Third member of FDA advisory panel resigns over Alzheimer's drug approval

The resignations are in protest over the company’s determination to approve Biogen Inc’s Alzheimer’s remedy regardless of the committee’s advice in opposition to doing so.

Leave a Reply

Your email address will not be published. Required fields are marked *